Cargando…

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option

Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the only effective therapeutic approaches for advanced hepatocellular carcinoma (HCC). This underlines the importance of RAS-RAF-ERK-signaling in HCC. Most RAS isoforms were no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietrich, Peter, Freese, Kim, Mahli, Abdo, Thasler, Wolfgang Erwin, Hellerbrand, Claus, Bosserhoff, Anja Katrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790486/ https://www.ncbi.nlm.nih.gov/pubmed/29423069 http://dx.doi.org/10.18632/oncotarget.23188

Ejemplares similares

Xanthohumol, a Prenylated Chalcone Derived from Hops, Inhibits Growth and Metastasis of Melanoma Cells
por: Seitz, Tatjana, et al.
Publicado: (2021)

Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro
por: Mahli, Abdo, et al.
Publicado: (2019)

Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
por: Seitz, Tatjana, et al.
Publicado: (2020)

Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice
por: Sommer, Judith, et al.
Publicado: (2016)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma()
por: Dietrich, Peter, et al.
Publicado: (2019)

Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury
por: Sommer, Judith, et al.
Publicado: (2020)

The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression
por: Dietrich, Peter, et al.
Publicado: (2019)

Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro
por: Kersten, Vanessa, et al.
Publicado: (2023)

Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells
por: Koch, Andreas, et al.
Publicado: (2015)

Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease
por: Mahli, Abdo, et al.
Publicado: (2019)

The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels
por: Weiskirchen, Ralf, et al.
Publicado: (2015)

Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro
por: Mahli, Abdo, et al.
Publicado: (2015)

Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche
por: Seitz, Tatjana, et al.
Publicado: (2022)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma
por: Linck-Paulus, Lisa, et al.
Publicado: (2020)

UVB radiation represses CYLD expression in melanocytes
por: Kuphal, Silke, et al.
Publicado: (2017)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

Expression and Function of Methylthioadenosine Phosphorylase in Chronic Liver Disease
por: Czech, Barbara, et al.
Publicado: (2013)

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma
por: Fritz, Valerie, et al.
Publicado: (2021)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11
por: Gaza, Anne, et al.
Publicado: (2021)

Complex Formation with Monomeric α-Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun’s Nuclear Translocation and Activity
por: Kappelmann-Fenzl, Melanie, et al.
Publicado: (2019)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Targeting Melanoma Metastasis and Immunosuppression with a New Mode of Melanoma Inhibitory Activity (MIA) Protein Inhibition
por: Schmidt, Jennifer, et al.
Publicado: (2012)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2017)

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020)

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma
por: Massoumi, Ramin, et al.
Publicado: (2009)

PLK1 plays dual roles in centralspindlin regulation during cytokinesis
por: Adriaans, Ingrid E., et al.
Publicado: (2019)

Dual Inhibition of γ-Tubulin and Plk1 Induces Mitotic Cell Death
por: Ebisu, Haruna, et al.
Publicado: (2021)

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
por: Carr, Ryan M., et al.
Publicado: (2021)

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2014)

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
por: Hyoda, Tomoko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qk9kqpo91peflitov7vt4aj63u